October 1, 2021 Columns by Beth Ullah I Think, Therefore I Am More Than My Mental Fatigue āA river cuts through rock not because of its power, but because of its persistence.ā ā James N. Watkins Fatigue is arguably the most disruptive symptom of multiple sclerosis (MS). At least it is for me. It has an awful lot to answer for. And it will.
September 22, 2021 News by Somi Igbene, PhD Stopping Fingolimod ā Gilenya ā for Pregnancy Raises Relapse Risk Women with relapsing-remitting multiple sclerosis (MS) who suspend their use of fingolimod ā sold as Gilenya, among others ā to conceive or during the early stages of pregnancy have a significantly higher risk of relapse during and after pregnancy, a new study finds. Stopping fingolimod resulted in a…
August 17, 2021 News by Marta Figueiredo, PhD Ocrevus Effective in RRMS Patients With Poor Responses to Prior DMTs Ocrevus (ocrelizumab) safely and effectively prevents relapses and disease progression in relapsing-remitting multiple sclerosis (RRMS) patients who responded poorly to other disease-modifying therapies (DMTs), final two-year data from the CHORDS Phase 3b clinical trial show. Notably, these benefits also were observed among patients who enrolled in the study…
July 14, 2021 News by Marta Figueiredo, PhD Kesimpta for RRMS Now Available in Scotland at Low or No Cost Adults in Scotland with active relapsing-remitting multiple sclerosis (RRMS) will now have access at low or no cost to Kesimpta (ofatumumab), the first self-administered, at-home B-cell-targeting therapy for people with the neurodegenerative disease. The Scottish Medicines Consortium (SMC) recommended that the Novartis therapy be available through the…
July 14, 2021 News by Marta Figueiredo, PhD Biogen Strikes Deal for Orelabrutinib, Now in Phase 2 Trial Biogen has signed a deal with InnoCare Pharma to acquire global commercialization and licensing rights to orelabrutinib, anĀ experimental oral BTK inhibitor (BTKi) now being tested in people with relapsing-remitting multiple sclerosis (RRMS) in a Phase 2 clinical trial. Under the terms of the agreement, Biogen will have…
March 25, 2021 News by Diana Campelo Delgado Dosing Begins in Trial of Anokion’s ANK-700 for RRMS A Phase 1 clinical trial investigating ANK-700 as a means to restore immune tolerance to myelin in people multiple sclerosis (MS) has begun dosing participants. Currently recruiting at a single site in Tennessee, the trial (NCT04602390) is expected to enroll up to 40 patients with relapsing-remitting…
March 24, 2021 News by Forest Ray PhD Health Canada OKs Self-administered Kesimpta for Adults With Active RRMS Health Canada has approvedĀ Kesimpta (ofatumumab) for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) who have active disease, as defined by clinical and imaging features. In contrast with other B-cell-targeting therapies used in MS, patients can self-administer a precise dose of Kesimpta at home using the Sensoready…
July 7, 2020 News by Marta Figueiredo, PhD Study: Mavenclad Shows Long-term Effectiveness at Preventing MS Relapses, Disease Progression MavencladĀ (cladribine) prevents relapses and disease progression in more than half of patients with relapsing forms of multiple sclerosis (MS) for at least five years after the last dose, according to a real-life study from Italy. These findings, based on real-world data from Italian MS patients previously treated…
August 23, 2019 News by Ana Pena PhD Rituximab Leads to ‘Dramatic’ Recovery in Boy with Aggressive RRMS, Case Study Reports Treatment with rituximabĀ ā sold as RituxanĀ in the U.S. by RocheĀ and Biogen, and asĀ MabThera byĀ Roche in Europe ā reversed disease course in a “dramatic fashion,” leading to complete remission in a 12-year-old boy with aggressiveĀ relapse-remitting multiple sclerosis (RRMS), a case report states. The report, “…
May 21, 2019 News by Ana Pena PhD Fibrinogen-containing Vesicles in Blood May Play Key Role in MS Relapses, Mouse Study Suggests Vesicles in the blood that contain a protein called fibrinogen important for blood clotting were found to be “sufficient and required” for the occurrence of spontaneous disease relapses in mouse models of multiple sclerosis (MS), a study reports. In mice, these vesicles were associated with immune cell infiltration, inflammation,…
April 25, 2019 News by Vijaya Iyer, PhD Aubagio Lowers Relapse Rate in RRMS Patients, Real-world Observational Study Shows In clinical practice, relapse events dropped by roughly half over a four-year period inĀ relapsing-remitting multiple sclerosisĀ (RRMS) patients treated withĀ Aubagio (teriflunomide), a real-world study reports. The study, āReal-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study,ā also examined patients’ perspectives in…
December 11, 2018 Columns by Ed Tobias Consensus Lacking on How MS Medications Are Prescribed in the UK Living in the U.S., where disease-modifying therapies (DMTs) seem to be prescribed as a matter of course to people with multiple sclerosis (MS), I was surprised that it doesn’t seem to be the case across the pond in the U.K. An article just published on the Multiple…
December 3, 2018 Columns by Ed Tobias MS News that Caught My Eye Last Week: MRI Dyes, Lipids and MS, Gilenya Advisory, Possible Stem Cell Trial Artificial Intelligence May Help Reduce Dosage of Gadolinium in MRIs, Researchers Suggest There’s been concernĀ recently about the accumulation of gadolinium in the brains of people who’ve had MRIs. Gadolinium is the dye that’s used to provide the “contrast” that can highlight lesions in the brain that might…
August 15, 2018 News by Patricia Inacio, PhD Long-term DMT Use Seen to Lower Likelihood of RRMS Progressing to SPMS in Study Long-term treatment with disease-modifying therapies (DMTs) appears to lessen the risk of disease worsening inĀ relapsing-remitting multiple sclerosis (RRMS) patients, an 18-year follow-up study suggests. But these therapies were not seen to benefit those who had progressed to secondary progressive multiple sclerosis (SPMS). The study, āOnset of secondary…
May 3, 2018 Columns by Laura Kolaczkowski Ocrevus Shows Promise for Cognitive Function in Relapsing MS One thing weāve all hoped for with our disease-modifying therapies (DMT) is a treatment that will improve our multiple sclerosis (MS) and not just keep it from worsening. The latest studies presented on Ocrevus (ocrelizumab) hold promise that this treatment may have finally arrived. According to recent reports,…
January 19, 2016 News by admin Anti-LINGO-1: All You Need to Know Recently, Biogen released results from its Phase 2 acute optic neuritis (AON) RENEW trial which tested Anti-LINGO-1. Learn more about this results here. So what isĀ Anti-LINGO-1? According to the MS Society,Ā Anti-LINGO-1 (also known as BIIB033) is a treatment in development by the pharmaceutical company Biogen which is currently…
April 15, 2015 News by Patricia Silva, PhD Beta-Interferon Therapy Has No Effect on Secondary Progressive MS Onset According to Study A team led by researchers at the University of British ColumbiaĀ in Canada recently published results in the European Journal of NeurologyĀ showing thatĀ treatment with beta-interferon has no effect on secondary progressive multiple sclerosis (MS) disease onset. The study is entitled āBeta-interferon exposure and…